CLINICAL TRIALS PROFILE FOR AZD5055

Clinical Trials for AZD5055

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT05134727 ↗	Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants	Not yet recruiting	AstraZeneca	Phase 1	This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
NCT05630677 ↗	A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.	Recruiting	Parexel	Phase 1	This study will estimate the relative bioavailability of AZD5055 film-coated tablet as compared to AZD5055 oral suspension. The study will also assess the absolute bioavailabilty of AZD5055 and the effect of food and an acid reducing agent, rabeprazole, on the PK of AZD5055 film-coated tablets when given with food (fed state) or without food (fasted state).
NCT05630677 ↗	A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.	Recruiting	AstraZeneca	Phase 1	This study will estimate the relative bioavailability of AZD5055 film-coated tablet as compared to AZD5055 oral suspension. The study will also assess the absolute bioavailabilty of AZD5055 and the effect of food and an acid reducing agent, rabeprazole, on the PK of AZD5055 film-coated tablets when given with food (fed state) or without food (fasted state).
NCT05644600 ↗	A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Subjects.	Not yet recruiting	Parexel	Phase 1	The study is intended to quantify the effect of co-administration of AZD5055 on exposures of nintedanib in healthy subjects.
NCT05644600 ↗	A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Subjects.	Not yet recruiting	AstraZeneca	Phase 1	The study is intended to quantify the effect of co-administration of AZD5055 on exposures of nintedanib in healthy subjects.
NCT05955183 ↗	Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..	Completed	AstraZeneca	Phase 1	This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD5055 after single and multiple doses, orally administered in healthy Japanese and Chinese participants.

Clinical Trial Conditions for AZD5055

Condition Name

Condition Name
Intervention	Trials
Healthy Participants	1
Healthy Subjects	1
Healthy Volunteers	1
Idiopathic Pulmonary Fibrosis	1

Condition MeSH

Condition MeSH
Intervention	Trials
Idiopathic Pulmonary Fibrosis	1
Pulmonary Fibrosis	1

Clinical Trial Locations for AZD5055

Trials by Country

Trials by Country
Location	Trials
United States	3
United Kingdom	1

Trials by US State

Trials by US State
Location	Trials
Maryland	2
California	1

Clinical Trial Progress for AZD5055

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 1	4

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Not yet recruiting	2
Completed	1
Recruiting	1

Clinical Trial Sponsors for AZD5055

Sponsor Name

Sponsor Name
Sponsor	Trials
AstraZeneca	4
Parexel	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	6